Ask AI

Hematologic Malignancies

Share

Program Content

Activities

  • ASC2ESCALATE
    ASC2ESCALATE: Phase II Trial of Asciminib in Patients With CML-CP After 1 TKI
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2025

    Expires: December 01, 2025

  • ASC4START
    ASC4START: Phase IIIb Trial of Asciminib vs Nilotinib in Newly Diagnosed Ph+ Chronic-Phase Chronic Myeloid Leukemia
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2025

    Expires: December 05, 2025

  • ctDNA MRD
    Prognostic Value of ctDNA-MRD by PhasED-Seq at the End of First-line Treatment for DLBCL in a National Cohort
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2025

    Expires: December 08, 2025

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation